{
    "clinical_study": {
        "@rank": "42051", 
        "arm_group": {
            "arm_group_label": "NVAF patients in Mexico treated with Apixaban", 
            "description": "All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to identify and describe any suspected (AEs) in all\n      patients with NVAF treated with Apixaban, as a request of the National Center of\n      Pharmacovigilance (CNFV) in Mexico."
        }, 
        "brief_title": "Early Post-marketing Study of Eliquis (Apixaban)", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-valvular Atrial Fibrillation (NVAF)", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  All patients with NVAF at the sentinel site for the CNFV in Mexico who received at\n             least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the\n             specified 24-month study period\n\n        Exclusion Criteria:\n\n          -  Subjects who received Apixaban as part of a clinical trial\n\n          -  Subjects who received Apixaban for any indication other than local approval (ie, to\n             reduce the risk of stroke and systemic embolism in patients with NVAF)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The sentinel site for the CNFV in Mexico"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153424", 
            "org_study_id": "CV185-330"
        }, 
        "intervention": {
            "arm_group_label": "NVAF patients in Mexico treated with Apixaban", 
            "intervention_name": "Apixaban", 
            "intervention_type": "Drug", 
            "other_name": "Eliquis"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "number_of_groups": "1", 
        "official_title": "Early Post-marketing Study of Eliquis (Apixaban)", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Mexico: Secretaria de Salud", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Determine the reporting rate of on-treatment adverse events (AEs) by the treating physicians", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 month study period"
            }, 
            {
                "measure": "Identify, describe, and report any suspected AEs that occur while on treatment with Apixaban or preventing stroke and systemic embolism in patients with NVAF", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153424"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}